University Of Pittsburgh Cancer Institute Defines First Immunologic Markers Of Interferon Effectiveness Against Melanoma

PITTSBURGH, May 17 -- For the first time, investigators have correlated the use of interferon alfa 2b (IFNa2b) with specific immune responses in patients treated with high doses of this agent to prevent the recurrence of melanoma. These findings, part of a landmark multi-center study based at the University of Pittsburgh Cancer Institute (UPCI), begin to account for the impact of IFNa2b on relapse-free survival among study patients. The results shed light on how this biological therapy works and provide signposts that could one day help clinicians pinpoint which patients will benefit from therapy, according to the investigators, who are presenting their preliminary findings Monday, May 17, at the annual meeting of the American Society of Clinical Oncology in Atlanta.

"This is the first attempt to make immunologic sense of the effects of IFNa2b on patients receiving this drug to prevent the recurrence of melanoma," said John Kirkwood, M.D., professor of medicine at the University of Pittsburgh and director of UPCI's Melanoma Center. "We found evidence that high-dose IFNa2b modulated the body's expression of cell markers called MHC Class II antigens on tumor tissues. These markers are necessary for the anti-tumor activity of one group of immune cells, or helper T cells. High-dose interferon also increased the response of a special set of immune cells, called natural killer cells, which may be more broadly active against melanoma cells."

Interferons are biological response modifiers produced naturally by the body to fight infections and tumors. IFNa2b is manufactured for use in cancer treatment studies, and can cause flu-like symptoms and depression in people receiving it.

The immunologic findings were made during a large study of high-dose IFNa2b, low-dose IFNa2b or observation for patients with surgically removed melanoma considered at high risk of recurrence. Results of this study have shown that recipients of a yearlong course of high-dose

Contact: Lauren Ward
University of Pittsburgh Medical Center

Page: 1 2

Related medicine news :

1. Indiana University researchers closer to helping hearing-impaired using stem cells
2. Boston University team finds link between high cholesterol and better cognitive performance
3. University seeks recruits for arthritis study
4. University of Manchester awarded 826k for brain science and mental health research
5. $4 million grant boosts University of Michigan campaign for a new childrens hospital
6. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
7. Next generation body scanner launched by the University of Manchester
8. University of Washington joins new Autism Treatment Network to provide better medical services
9. Binghamton University launches microelectronics research center
10. University of Manchester makes made-to-measure skin and bones a reality using inkjet printers
11. RelayHealth selected by Columbia University to link doctors and patients online

Post Your Comments:

(Date:9/1/2020)... Calif. (PRWEB) , ... September 01, 2020 , ... ... a new practice in Glendale. While the office will be the ... as breast augmentation, tummy tucks, buttock augmentation (Brazilian butt lift), as well as ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... are joining biomedical engineers from Carnegie Mellon University (CMU) to develop a new ... who have undergone open heart surgery. , The AGH/CMU team was recently awarded ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... for chiropractors, announced today the launch of its integrated, HIPAA compliant, telehealth solution, ... their virtual practice in under 90 seconds. , According to the U.S. ...
(Date:8/31/2020)... , ... August 31, 2020 , ... In an effort ... Loop is donating 10 percent of each hotel room booked with a special ... of Chicagoland & Northwest Indiana (RMHC-CNI) , effective immediately. Donations will be applied ...
(Date:8/28/2020)... ... 2020 , ... WHAT , Hespiro™ is a new type ... including COVID-19, while reducing the need for scarce mechanical ventilators. It not only ... scrubs it free of carbon dioxide in a completely closed “rebreather” system, important ...
Breaking Medicine News(10 mins):
(Date:8/31/2020)... PHOENIX (PRWEB) , ... August 31, 2020 , ... ... Mobile Sanitizing and Disinfecting - a broad-spectrum sanitization, disinfection and deodorization provider ... company will offer door-to-door sanitizing and disinfecting services for businesses and residents throughout ...
(Date:8/27/2020)... ... August 27, 2020 , ... InfoMC, a leading provider of ... their 2020 System and Organizational Controls (SOC) 1® Type 2 and SOC 2® ... assessment. These achievements reflect their long-standing commitment to privacy, security, and risk management, ...
(Date:8/27/2020)... ... August 27, 2020 , ... Bridge To A Cure Foundation ... is an adult and pediatric neuro-oncologist who serves on the Board of Directors at ... at Duke University Medical School. , Internationally recognized, Dr. Friedman is a widely published ...
Breaking Medicine Technology:
Cached News: